Interferon Alpha-2a as Treatment for Primary Acquired Melanosis with Atypia (PAMwA) and for PAMwA surrounding conjunctival melanoma

Key Points

• Interferon alpha-2a treatment shows promise in managing primary acquired melanosis with atypia.
• Remarkably, 75% of treated cases exhibited significant reduction in atypical melanocytic cells within three months.
• This observational study evaluates treatment efficacy based on tumor microenvironment assessments and clinical observations.
• Findings highlight the potential for interferon alpha-2a in improving outcomes for patients with PAMwA and related melanoma.